# OnCo record endometrial-pole-ultramutated (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/endometrial-pole-ultramutated/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "endometrial-pole-ultramutated" ;
  schema:name "POLE-ultramutated endometrial cancer"@en ;
  schema:alternateName "POLEmut endometrial cancer"@en, "POLE exonuclease domain mutant endometrial carcinoma"@en, "Ultramutated endometrial cancer"@en ;
  schema:description "POLE-ultramutated endometrial cancer carries a fault in the proofreading part of a DNA-copying enzyme, so its cells pile up enormous numbers of mutations. It looks aggressive under the microscope yet almost never comes back after surgery, so trials are testing whether radiotherapy and chemotherapy can be dropped altogether."@en ;
  schema:url <https://onco.cc/cancers/endometrial-pole-ultramutated/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Endometrial_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Endometrial_cancer> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/ideas/idea-molecular-class-adjuvant-endometrial/>, <https://onco.cc/terms/endometrial-molecular-classes/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:standardOfCare <https://onco.cc/terms/endometrial-molecular-classes/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/trials/fires-sentor/>, <https://onco.cc/terms/hysterectomy/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/terms/endometrial-molecular-classes/>, <https://onco.cc/ideas/idea-molecular-class-adjuvant-endometrial/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/portec-3/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/technologies/checkpoint-inhibitor/> .